Press Releases

July 28th, 2020

HemoShear Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for HST5040 to Treat Methylmalonic Acidemia and Propionic Acidemia

Read More »
July 9th, 2020

HemoShear Therapeutics Achieves Milestone in Exclusive Drug Discovery Collaboration with Horizon Therapeutics in Gout

Read More »
June 24th, 2020

HemoShear Therapeutics Receives FDA Clearance of IND for Phase 2 Study of its Investigational Drug HST5040 for the Treatment of Methylmalonic Acidemia and Propionic Acidemia

Read More »
September 25th, 2019

HemoShear Therapeutics Appoints Brian A. Johns, PhD, Chief Scientific Officer

Read More »
August 6th, 2019

HemoShear Therapeutics to Present at Wedbush PacGrow Healthcare Conference

Read More »
June 19th, 2019

HemoShear Therapeutics Names Biopharma Veteran Kathleen M. Metters, PhD, to Board of Directors

Read More »
March 20th, 2019

Takeda and HemoShear Therapeutics Extend Exclusive Drug Discovery Partnership in Liver Diseases

Read More »
March 6th, 2019

HemoShear Therapeutics Physiological Human Tumor Model Published in Lab on a Chip Journal

Read More »
January 3rd, 2019

Horizon Pharma Plc and HemoShear Therapeutics Enter Into Exclusive Drug Discovery Collaboration in Gout

Read More »
December 4th, 2018

Carnot Biosciences, A Spin Off Of Smartzyme Biopharma, And Hemoshear Therapeutics Partner To Develope Protein-Based Therapeutics For Rare Metabolic Diseases

Read More »
March 8th, 2018

HemoShear Therapeutics And Children’s National Rare Disease Institute To Present Data On Four Research Programs In Children’s Rare Diseases At The Society For Inherited Metabolic Disorders Meeting

Read More »
October 17th, 2017

Takeda and HemoShear Therapeutics Enter Into Exclusive Drug Discovery Partnership in Liver Diseases

Read More »
View More +

Contact

info@hemoshear.com

501 Locust Avenue
Suite 301
Charlottesville, Virginia 22902